Literature DB >> 6712030

Transaminase elevations in patients receiving bovine or porcine heparin.

G E Dukes, S W Sanders, J Russo, E Swenson, T G Burnakis, J R Saffle, G D Warden.   

Abstract

Eighty-six patients who required heparin therapy were randomly assigned to receive bovine or porcine heparin. Abnormal concentrations of alanine transaminase and aspartate transaminase developed during treatment in 59.3% and 26.7% of patients, respectively. Patient characteristics that significantly influenced the development of abnormal alanine transaminase concentrations were male sex and higher baseline enzyme values. Transaminase concentrations returned to normal in 80% of patients after heparin therapy was discontinued and in 20% during therapy. Analysis of transaminase concentrations in all 86 patients showed that 95% had some increase in enzymes during treatment. Mean maximal increase over baseline for all patients was 3.6 for alanine transaminase and 3.1 for aspartate transaminase (range, 1.0 to 15). Lactate dehydrogenase concentrations became abnormal in 35.7% of patients. Lactate dehydrogenase isoenzyme determinations in 6 patients showed elevated hepatic fractions. No clinical symptoms of hepatic dysfunction were seen.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6712030     DOI: 10.7326/0003-4819-100-5-646

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

Review 1.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

Review 2.  In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.

Authors:  Rachel J Church; Paul B Watkins
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-02

Review 3.  The transformation in biomarker detection and management of drug-induced liver injury.

Authors:  Rachel J Church; Paul B Watkins
Journal:  Liver Int       Date:  2017-05-08       Impact factor: 5.828

4.  Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.

Authors:  Paul B Watkins; Mehul Desai; Scott D Berkowitz; Gary Peters; Yves Horsmans; Dominique Larrey; Willis Maddrey
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

5.  Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia.

Authors:  M Monreal; E Lafoz; R Salvador; J Roncales; A Navarro
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 7.  Long-term anticoagulation. Indications and management.

Authors:  B M Stults; W H Dere; T H Caine
Journal:  West J Med       Date:  1989-10

8.  The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.

Authors:  A H Harrill; J Roach; I Fier; J S Eaddy; C L Kurtz; D J Antoine; D M Spencer; T K Kishimoto; D S Pisetsky; B K Park; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2012-06-27       Impact factor: 6.875

Review 9.  Enoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS).

Authors:  Katherine J Hahn; Shannon J Morales; James H Lewis
Journal:  Drug Saf Case Rep       Date:  2015-12

Review 10.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.